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Malignant pleural effusion (MPE) not only represents a very 
common cause of pleural exudates, but is also one of the most 
challenging pleural disorders to manage, given the paucity of high-
quality evidence and the heterogeneity of practice worldwide.[1,2] 
Between 30% and 50% of all patients with metastatic malignancies 
will have pleural involvement at autopsy, and approximately half of 
these will have pleural effusions, which range from insignificant to 
massive.[2,3]
MPE may complicate most malignancies, although lung and breast 
cancer remain the most common causes.[2] Evidence suggests that 
MPE is most often caused by haematogenous spread of malignant 
cells to the visceral pleura with secondary seeding to the parietal 
pleura.[4] MPE generally signifies incurable disease with a poor 
prognosis.[2] Median survival is ~3 - 12 months, but can vary 
significantly according to cell type, performance status of the patient, 
staging and whether a chemosensitive malignancy is present.[2] 
The two most common non-surgical interventions are intercostal 
drainage (ICD) with pleurodesis to obliterate the pleural space, or 
indwelling pleural catheters (IPCs) that provide continuous drainage 
of the pleural cavity and may potentially cause autopleurodesis.[2,5]
We previously showed that adenocarcinoma had surpassed 
squamous cell carcinoma as the predominant cell type in lung 
cancer patients in our setting, which is in keeping with international 
trends. [6,7] To the best of our knowledge, there are no data regarding 
the aetiology of MPE for either the Western Cape Province or South 
Africa (SA).
Objectives
The primary objective of this study was to identify the most common 
pleural malignancies leading to MPE in the population served by 
a large tertiary hospital in the Western Cape, and specifically the 
relative contribution of mesothelioma. The secondary objective was 
to evaluate the radiological efficacy of chemical pleurodesis, which 
was offered to selected patients.
Methods
Study design and population
We retrospectively identified and included all known cases of 
MPE, defined as malignant cells present on pleural fluid analysis or 
pleural biopsy, that were managed at our institution from January 
2014 to December 2016. We identified: (i) cases managed by the 
Division of Pulmonology at Tygerberg Academic Hospital; and 
(ii) all other known cases (not referred to our division) with a 
cytological or histological diagnosis of MPE made by the Division 
of Anatomical Pathology, Tygerberg Academic Hospital, National 
Health Laboratory Service (NHLS). Tygerberg Academic Hospital is 
a 1 380-bed facility in Cape Town, SA. It is one of two referral centres 
in the city and renders a tertiary service to a population of ~3.0 
million people. We used the hospital’s existing lung cancer registry to 
identify all cases of pleural malignancy presented at the lung cancer 
board meeting as well as the theatre records to identify any potential 
patients who underwent pleural procedures related to MPE. We also 
searched the NHLS records to specifically identify all other cases that 
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were not managed by the division. Duplicate entries were removed if 
encountered.
Ethics approval
The study was conducted in accordance with the principles outlined 
in the Declaration of Helsinki and local and international good 
clinical practice guidelines. Ethical approval was obtained from the 
Health Research Ethics Committee of Stellenbosch University (ref. 
no. S15/10/233).
Primary diagnoses and further analyses
Primary underlying diagnoses were based on confirmatory cytology/
histology with definitive imaging and/or immunohistochemistry/
immunocytochemistry profiling of malignant cells, or a known history 
of active extrapleural malignancy (with proven spread to the pleura).
Imaging
We categorised the size of pleural effusion on the chest radiograph 
into three categories: small (less than one-third of the hemithorax), 
moderate (one-third to two-thirds of the hemithorax) and large 
(more than two-thirds of the hemithorax). Computed tomography 
scans, when available, were reviewed and evaluated for pleural 
thickening (defined as ≥10 mm) and nodularity of both visceral and 
parietal layers, diaphragmatic thickening (defined as a diaphragmatic 
diameter >7 mm), and liver metastasis.
Pleurodesis
Pleurodesis was routinely offered to patients with symptomatic MPE, 
provided they experienced relief of dyspnoea after thoracentesis, had 
no trapped lung and had a predicted life expectancy of >3 months. 
Patients who underwent chemical pleurodesis using talc slurry were 
identified from the division’s records, and the radiological success 
rate at 3-month follow-up was documented. Successful pleurodesis 
was defined as lack of reaccumulation of pleural fluid collection.
Statistical analysis
Descriptive statistics and χ2 comparisons of proportional data were 
performed. A p-value <0.05 in a two-tailed test of proportions 
(χ2) was considered significant. The data were presented as means 
(standard deviation (SD)).
Results
A total of 274 cases (mean age 59.3 (SD 12.5) years, 123 males) of 
MPE were identified: 194 from the division’s records (an average of 
65 per year) and a further 80 from the NHLS database. The primary 
underlying diagnoses are summarised in Table 1, with the most 
common being lung cancer (n=174, 63.5%), breast cancer (n=32, 
11.7%, malignant mesothelioma (n=27, 9.9%) and unknown primary 
(n=22, 11.7%).
Table 2 provides a summary of the radiological findings. The size 
of pleural effusion in patients with mesothelioma was mainly large 
(n=11, 52.3% of all mesothelioma patients), followed by moderate 
(n=7, 33.3%) and small (n=3, 14.2%). In lung cancer, the size was 
approximately equally spread from small to large. In breast cancer, 
moderate-sized effusions (n=12, 46.1%) were the most common. 
Pleural thickening and nodularity in mesothelioma were parietal 
(n=11, 52.3%) and visceral (n=9, 42.8%).
Chemical pleurodesis was performed in 81 of 194 cases (41.8%) 
managed by our division, and was successful in 22 (88.0%) of 25 
patients followed up at 3 months.
Discussion
In our patient population, the most common causes of MPE were lung 
cancer (63.5%), breast cancer (11.7%), unknown primary (11.7%) 
and mesothelioma (9.9%). In patients who were offered chemical 
pleurodesis and followed up for at least 3 months, pleurodesis was 
successful in nearly 90%.
Our findings are in line with international trends, with the one 
exception being the relatively small proportion of lymphomas.[2] This 
is surprising, given the relatively high prevalence of HIV infection 
in our population and the known association between HIV and 
lymphomas.[8] Possible explanations may include lack of referral 
Table 1. The causes of malignant pleural effusion (N=274)
Causes Tissue type n (%) 
Primary Mesothelioma 27 (9.9) 
Other 0
Secondary Lung 174 (63.5) 
Adenocarcinoma 115 (66.1)
Squamous cell 15 (8.6)
NSCLC – non-specified 20 (11.5)
Undifferentiated/large cell 3 (1.7)
SCLC 21 (12.1)
Breast 32 (11.7)
Unknown primary 22 (8.0)
Gynaecological 9 (3.3)
Gastrointestinal 3 (1.1)
Lymphoma 3 (1.1)
Other* 4 (1.5)
NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer.
*Skin cancer (n=1), prostate cancer (n=1), sarcoma (n=1), renal cell carcinoma (n=1).
Table 2. Radiological features of malignant pleural effusion (N=194), %
Size of pleural effusion
Pleural thickening or 
nodularity Diaphragmatic 
thickening >7 mm Liver metastasis<1/3 1/3 - 2/3 >2/3 Visceral Parietal
Mesothelioma 14.2 33.3 52.3 42.8 52.3 28.5 9.5
Lung
Adenocarcinoma 25.0 38.6 36.3 11.3 11.3 2.2 29.1
Squamous cell 33.3 33.3 33.3 6.6 20.0 6.0 26.6
Undifferentiated 27.7 44.4 27.7 11.1 11.1 0 16.6
SCLC 27.7 61.1 11.1 22.2 0 0 27.7
Breast 23.0 46.1 30.7 3.8 11.5 3.8 26.9
Other 12.5 50.0 37.5 12.5 12.5 12.5 12.5
SCLC = small-cell lung cancer.
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from outside doctors, owing to misdiagnoses as pleural tuberculosis 
or presumptive diagnoses of pleural involvement in patients known 
to have lymphoma and imaging compatible with pleural spread (e.g. 
positive positron emission tomography-computed tomography). 
We also did not observe a female predominance as is sometimes 
reported,[9] arguably because in our cohort breast cancer was only 
responsible for just over 10% of MPEs.
The fact that 1 in 10 MPEs were in patients with malignant meso-
thelioma, almost a decade after asbestos was finally banned in SA, 
remains a significant finding.[10] The latency period after exposure 
to asbestos is known to be very prolonged, with almost all cases seen 
≥15 years after exposure.[11] Moreover, the estimated median latent 
period is at least 30 years after the initial exposure.[11]
The incidence of mesothelioma peaked around 2015 in the UK, 
but in contrast may continue to increase in resource-limited settings 
secondary to poor regulation of industrial and household utilisation 
of asbestos.[12] Mesothelioma is therefore expected to continue to 
account for a significant proportion of MPE in our setting for at least 
another two to three decades.
The two most common approaches to MPE are IPCs or chemical 
pleurodesis via rigid or semirigid thoracoscopy or ICD.[2] IPCs 
were only introduced to our service in the latter half of 2015, and 
pleurodesis was therefore the most common form of palliation 
offered for dyspnoea during the study period. The proportion 
of patients offered pleurodesis (41.8%) as well as the 3-month 
radiological success rate of 88.0% are on par with reported figures, 
which generally range from 30% to 50% and from 75% to 90%, 
respectively.[9]
Study strengths and limitations
One of the strengths of our study is the fact that we did not limit 
our cohort to patients referred to our unit. We anticipated that 
a significant proportion of patients would be managed by other 
disciplines, which proved to be the case in 80 of 274 cases. An obvious 
limitation is the retrospective nature of the study and possible 
selection bias, as patients with advanced malignancy may have been 
referred directly for palliative care, without further investigations. 
Further, loss to follow-up in the pleurodesis group limits the 
conclusions with regard to the apparent high success rate of chemical 
pleurodesis. Our sample size was restricted to cases seen over a 3-year 
period, which could limit the general applicability of our findings to 
the greater SA context.
Conclusions
We identified that the main cause of MPE was lung cancer, 
followed by breast cancer, unknown primary and mesothelioma. 
The proportion of mesothelioma cases was both surprising and 
concerning. Chemical pleurodesis appears to be a viable palliative 
measure for MPE in our population.
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